UC Berkeley scientists report the first analysis of the genomes of eight bats from the genus Myotis, known for having the longest-lived species — 50 years. The analysis finds a close link between bat longevity and its immune system — longer-lived bats had higher levels of cancer-fighting genes. The analysis suggests that an immune system able to mount an overwhelming attack against infectious organisms and cancer may be integral to a long lifespan.

Bats are anomalies in the mammalian world—they fly, have long lifespans, and rarely get cancer. Scientists now suspect the bat immune system enables them to live longer without disease, according to a new study published today in Nature.

Patients treated with medication for benign prostatic hyperplasia at the time of a severe acute heart attack experienced fewer serious complications from the attack, according to a study from the University of Gothenburg.

More than 1.9 million people are diagnosed with colorectal cancer each year, making it the third most common cancer and the second leading cause of cancer death worldwide. 

Global cancer burden continues to shift, driven by population aging, lifestyle changes, and disparities in screening and prevention. 

BUFFALO, NY — August 26, 2026 — A new review was published in Volume 13 of Oncoscience on July 29, 2026, titled “Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy.”

Delivering drugs directly to oral tumor sites remains challenging. A recent review involving researchers from Hasanuddin University examines barriers to local drug delivery and analyses strategies for targeting oral cancer lesions. Saliva, chewing, tongue movement, and individual tumor characteristics can affect how long a medicine remains at the treatment site and how consistently it is released. Researchers emphasize tailoring delivery systems to the tumor, drug, and patient alongside realistic testing under clinical conditions.

In its CZS Nexus program, the Carl Zeiss Foundation has awarded grants to two young scientists from the Karlsruhe Institute of Technology (KIT). The researchers will each receive EUR 1.5 million to establish their own interdisciplinary working groups at KIT. Dr. Laura Marie Helleckes investigates how biotechnology processes can be transferred from the laboratory to industrial production. Dr. Bianca Schacherl uses modern X-ray techniques to gain new insights for cancer treatment by analyzing radioactive materials in biological samples.

A comprehensive new study has quantified for the first time the lifetime risk of developing and dying from breast cancer across 185 countries, revealing that 1 in 18 individuals worldwide will be diagnosed with the disease during their lifetime and 1 in 55 will die from it.